But Ozempic (semaglutide) is a weekly injection, and has also demonstrated superior efficacy to Trulicity in head-to-head trials. The Novo Nordisk drug was compared to Trulicity in its SUSTAIN 7 ...

Trulicity is still the market leader with sales of $4.13 billion last year, a rise of 29%, but Ozempic has been gaining ground. Novo Nordisk’s drug grew 142% in 2019 to $1.6 billion.

The GIP/GLP-1 dual agonist tirzepatide (Mounjaro) showed cardiovascular protective benefits over dulaglutide (Trulicity) in the phase III SURPASS-CVOT trial of diabetes patients with heart disease ...

Novo Nordisk is going all in on Ozempic, its once-weekly GLP-1 injection for diabetes that was approved by the FDA in December 2017. The Danish pharma has shifted marketing spend away from Victoza, ...

The U.S. Food and Drug Administration approved a new type 2 diabetes drug, Trulicity, on Thursday. Trulicity is part of a class of once-a-week injectable drugs that help manage blood sugar levels ...

Eli Lilly's Mounjaro matched Trulicity in heart outcomes and showed added benefits on A1C, weight, kidney function, and mortality in a major trial.

The study achieved its primary endpoint by demonstrating Mounjaro’s noninferiority to Trulicity in reducing the 3 major adverse cardiovascular events/MACE-3, which include cardiovascular death ...

[1/2]A pharmacist displays a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes made by Lilly at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023.

Lilly has presented results from a phase 3 trial in which Mounjaro measures up head-to-head against the company’s GLP-1 Trulicity in reducing cardiovascular risks in patients with Type 2 ...